Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593957 · ClinicalTrials.gov registry record · Phase 2
Trial of Dextromethorphan in Rett Syndrome
A Phase 2 study, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00593957 is a Phase 2 study that was terminated before completion, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 38 participants.
The verdict
NCT00593957, a Phase 2 study, was terminated before completion, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Increased brain glutamate and its N-methyl-D-aspartate (NMDA) receptors found in the brain of younger Rett syndrome (RTT) patients cause toxic damage to neurons (the brain's nerve cells), and contributing to EEG spikes. Dextromethorphan (DM) acts by blocking NMDA/glutamate receptors. This study is being done to determine if DM will prevent the harmful over-stimulation of the neurons thereby reducing EEG spike activity. Treatment with DM consists of one of 3 different doses (0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day), and aims to find out which dose if any will help improve EEG abnormalities, behavior, cognition, and reduce seizures, as well as improve breathing abnormalities, motor capabilities, bone density, and GI dysfunction. The study will include 90 females and males with RTT, 2 years-14.99 years of age, with a mutation in the methyl CpG binding protein 2 (MECP2) gene, and spikes on EEG, with or without clinical seizures.
Interventions
- DRUG Dextromethorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2004-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593957
The ClinicalTrials.gov registry entry for NCT00593957 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dextromethorphan is the first listed.
NCT00593957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00593957 about?
NCT00593957 is a clinical study titled "Trial of Dextromethorphan in Rett Syndrome". Increased brain glutamate and its N-methyl-D-aspartate (NMDA) receptors found in the brain of younger Rett syndrome (RTT) patients cause toxic damage to neurons (the brain's nerve cells), and contributing to EEG spikes. Dextromethorphan (DM) acts by blocking NMDA/glutamate receptors. This study is b...
What is the current status of trial NCT00593957?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2004-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00593957?
The interventions under investigation include: Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT00593957?
This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.